other material
confidence high
sentiment neutral
materiality 0.70
Atara amends Pierre Fabre deal; transfers manufacturing, reduces milestones; eligible for up to $550M
Atara Biotherapeutics, Inc.
- Transferred all manufacturing responsibility for tab-cel to Pierre Fabre as of March 31, 2025; Pierre Fabre will manufacture and supply worldwide at its cost.
- Pierre Fabre assumes remediation costs for third-party facility to address FDA requests and support BLA resubmission for tab-cel.
- Atara reduced certain potential future regulatory and commercial milestone payments in exchange for the accelerated transfer and cost assumption.
- Atara now entitled to aggregate of up to $550M in potential milestones, including up to $40M regulatory milestones for FDA BLA approval; royalties unchanged.